DAVITA INC. Revenue from Contract with Customer, Including Assessed Tax
DAVITA INC. (DVA) reported Revenue from Contract with Customer, Including Assessed Tax of $11.04 billion for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-12.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2021-02-12
- DAVITA INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-12-31 was $2.77B, a 1.40% increase year-over-year.
- DAVITA INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $2.78B, a 4.14% increase year-over-year.
- DAVITA INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-06-30 was $2.73B, a 0.58% increase year-over-year.
- DAVITA INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-03-31 was $2.64B, a 1.70% increase year-over-year.
- DAVITA INC. revenue from contract with customer, including assessed tax for fiscal 2020 was $11.04B, a 1.11% increase from fiscal 2019.
- DAVITA INC. revenue from contract with customer, including assessed tax for fiscal 2019 was $10.92B, a 1.95% increase from fiscal 2018.
- DAVITA INC. revenue from contract with customer, including assessed tax for fiscal 2018 was $10.71B, a 6.11% increase from fiscal 2017.
- DAVITA INC. revenue from contract with customer, including assessed tax for fiscal 2017 was $10.09B, a 3.77% increase from fiscal 2016.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $11.04B 10-K · filed 2021-02-12 | |||
| 2019-12-31 | $2.77B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $5.55B derived: sum of 2 quarters · filed 2021-02-12 | $8.28B derived: sum of 3 quarters · filed 2021-02-12 | $10.92B 10-K · filed 2021-02-12 |
| 2019-09-30 | $2.78B 10-Q · filed 2019-11-07 | $5.52B derived: sum of 2 quarters · filed 2019-11-07 | $8.15B 10-Q · filed 2019-11-07 | $10.88B derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-06-30 | $2.73B 10-Q · filed 2019-08-02 | $5.37B 10-Q · filed 2019-08-02 | $8.10B derived: sum of 3 quarters · filed 2021-02-12 | $10.77B derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-03-31 | $2.64B 10-Q · filed 2019-05-07 | $5.36B derived: sum of 2 quarters · filed 2021-02-12 | $8.04B derived: sum of 3 quarters · filed 2021-02-12 | $10.75B derived: sum of 4 quarters · filed 2021-02-12 |
| 2018-12-31 | $2.73B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $5.40B derived: sum of 2 quarters · filed 2021-02-12 | $8.12B derived: sum of 3 quarters · filed 2021-02-12 | $10.71B 10-K · filed 2021-02-12 |
| 2018-09-30 | $2.67B 10-Q · filed 2019-11-07 | $5.39B derived: sum of 2 quarters · filed 2019-11-07 | $7.98B 10-Q · filed 2019-11-07 | $10.59B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $2.72B 10-Q · filed 2019-08-02 | $5.31B 10-Q · filed 2019-08-02 | $7.92B derived: sum of 3 quarters · filed 2020-02-21 | $10.49B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $2.59B 10-Q · filed 2019-05-07 | $5.21B derived: sum of 2 quarters · filed 2020-02-21 | $7.77B derived: sum of 3 quarters · filed 2020-02-21 | $10.26B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $2.61B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $5.18B derived: sum of 2 quarters · filed 2020-02-21 | $7.67B derived: sum of 3 quarters · filed 2020-02-21 | $10.09B 10-K · filed 2020-02-21 |
| 2017-09-30 | $2.56B 10-Q · filed 2018-11-07 | $5.06B derived: sum of 2 quarters · filed 2018-11-07 | $7.48B 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $2.49B 10-Q · filed 2018-08-01 | $4.92B 10-Q · filed 2018-08-01 | ||
| 2016-12-31 | $9.73B 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |